FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Véronique Trillet-Lenoir

Research Profile

Procedures

Disorders

Concepts & Ideas

Chemicals & Drugs

Geographic Areas

France

Co-author Network

Publications

TOP 3
Jaafar Bennouna; Christophe Borg; Olivier Bouché; Jean-Pierre Delord; Roger Faroux; Eric François; François Goldwasser; Faress Husseini; Sandrine Kraemer; Helene Senellart; Véronique Trillet-Lenoir; Marc Ychou; Jean-Yves Douillard
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Alison Jones; Mary O'Brien; Harald Sommer; Elzbieta Nowara; Anja Welt; Tadeusz Pienkowski; Janusz Rolski; My-Linh Pham; Kevin Perraud; Véronique Trillet-Lenoir
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Bénédicte Poncet; Cyrille Colin; Thomas Bachelot; Isabelle Jaisson-Hot; Laure Derain; Laurent Magaud; Cécile Fournel-Federico; Mireille Mousseau; Jean-Dominique Tigaud; Jean-Philippe Jacquin; Véronique Trillet-Lenoir
Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Véronique Trillet-Lenoir (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Jaafar Bennouna; Christophe Borg; Olivier Bouché; Jean-Pierre Delord; Roger Faroux; Eric François; François Goldwasser; Faress Husseini; Sandrine Kraemer; Helene Senellart; Véronique Trillet-Lenoir; Marc Ychou; Jean-Yves Douillard
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Clinical colorectal cancer 2012;11(1):38-44.
2010: Alison Jones; Mary O'Brien; Harald Sommer; Elzbieta Nowara; Anja Welt; Tadeusz Pienkowski; Janusz Rolski; My-Linh Pham; Kevin Perraud; Véronique Trillet-Lenoir
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Cancer chemotherapy and pharmacology 2010;65(4):755-63.
2009: Bénédicte Poncet; Cyrille Colin; Thomas Bachelot; Isabelle Jaisson-Hot; Laure Derain; Laurent Magaud; Cécile Fournel-Federico; Mireille Mousseau; Jean-Dominique Tigaud; Jean-Philippe Jacquin; Véronique Trillet-Lenoir
Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab.
American journal of clinical oncology 2009;32(4):369-74.
2009: Emilie Hénin; Michel Tod; Véronique Trillet-Lenoir; Catherine Rioufol; Brigitte Tranchand; Pascal Girard
Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.
Clinical pharmacokinetics 2009;48(6):359-69.
2008: Benoit You; Brigitte Tranchand; Pascal Girard; Claire Falandry; Benjamin Ribba; Sylvie Chabaud; Pierre-Jean Souquet; Isabelle Court-Fortune; Véronique Trillet-Lenoir; Cécile Fournel; Michel Tod; Gilles Freyer
Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
Lung cancer (Amsterdam, Netherlands) 2008;62(2):261-72.
2008: Philippe A Cassier; Sylvie Chabaud; Véronique Trillet-Lenoir; Pierre-Yves Peaud; Jean-Dominique Tigaud; Hervé Cure; Hubert Orfeuvre; Bruno Salles; Claude Martin; Jean-Philippe Jacquin; Cecile Agostini; Jean-Paul Guastalla; David Pérol; Thomas Bachelot
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Breast cancer research and treatment 2008;109(2):343-50.
2008: Pascal Sève; Tony Reiman; Sylvie Isaac; Véronique Trillet-Lenoir; Laurence Lafanéchère; Michael Sawyer; Charles Dumontet
Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site.
Anticancer research 2008;28(2B):1161-7.
2007: Cécile Fournel-Federico; Benoît You; Véronique Trillet-Lenoir
[Targeted therapies in oncology].
La Revue du praticien 2007;57(19):2093-8.
2007: Didier Theis; Véronique Gilleron; Anne-Marie Schott; Fabienne Seguret; Véronique Trillet-Lenoir
[An overview of the 2001-2002 cancer activity in the 30 French Regional and University Hospitals, based on PMSI data].
Bulletin du cancer 2007;94(10):915-22.
2007: Bruno Coudert; Rémy Largillier; Laurent Arnould; Philippe Chollet; Mario Campone; David Coeffic; Frank Priou; Joseph GLIGOROV; Xavier Martin; Véronique Trillet-Lenoir; Béatrice Weber; Jean Pierre Bleuse; Berangère Vasseur; Daniel Serin; Moïse Namer
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2678-84.
2007: Bénédicte Poncet; Thomas Bachelot; C Colin; Hubert Orfeuvre; Christell Ganne; Pierre-Yves Péaud; JP Jacquin; B Salles; Jean-Dominique Tigaud; I Méchin-Crétinon; F Maréchal; Véronique Trillet-Lenoir
Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2007;19(2):162-3.
2007: François Golfier; C Labrousse; Lucien Frappart; Bruno Mathian; Jean-Paul Guastalla; Véronique Trillet-Lenoir; Touria Hajri; Anne-Marie Schott; Daniel Raudrant
[Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005].
Gynécologie, obstétrique & fertilité 2007;35(3):205-15.
2007: François Golfier; Daniel Raudrant; Lucien Frappart; Bruno Mathian; Jean-Paul Guastalla; Véronique Trillet-Lenoir; Fabien Vaudoyer; Touria Hajri; Anne-Marie Schott
First epidemiological data from the French Trophoblastic Disease Reference Center.
American journal of obstetrics and gynecology 2007;196(2):172.e1-5.
2007: Matti S Aapro; Pierfranco Conte; Emilio Esteban González; Véronique Trillet-Lenoir
Oral vinorelbine: role in the management of metastatic breast cancer.
Drugs 2007;67(5):657-67.
2006: Pascal Seve; ISABELLE RAY COQUARD; Véronique Trillet-Lenoir; Michael Sawyer; John Hanson; Christiane Broussolle; Sylvie Negrier; Charles Dumontet; John R Mackey
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site.
Cancer 2006;107(11):2698-705.
2006: Katy Foulmann; Jean-Paul Guastalla; Nadège Caminet; Véronique Trillet-Lenoir; Daniel Raudrant; François Golfier; Anne-Marie Schott
What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence.
Gynecologic oncology 2006;102(1):103-10.
2005: S Galand-Desmé; Laure Milliat-Guittard; Laurent Letrilliart; Antoine Duclos; Anne-Laure Charlois; Nicole Berthoux; P Méré; Véronique Trillet-Lenoir; Cyrille Colin
[Role of gynecologists in the care of women with breast cancer].
Journal de gynécologie, obstétrique et biologie de la reproduction 2005;34(8):775-80.
2005: Antoine Duclos; Véronique Trillet-Lenoir; Franck Chauvin; Cyrille Colin; Sandrine Touzet
[Physicians' opinions about the implementation of clinical practice guidelines for gastrointestinal oncology].
Presse médicale (Paris, France : 1983) 2005;34(12):851-5.
2005: Anne-Marie Schott; Touria Hajri; Bénédicte Gelas-Dore; Chantal Marie Couris; Sandrine Couray-Targe; Véronique Trillet-Lenoir; Bernard Dumeril; Jean Paul Grandjean; Gérard Lledo; Jean Luc Poncet; Cyrille Colin; Nicola Cautela; François Noël Gilly
[Analysis of the medical activity related to cancer in a network of multidisciplinary hospitals using claims databases, the reseau Concorde Oncology Network].
Bulletin du cancer 2005;92(2):169-78.
2004: Véronique Trillet-Lenoir; François Roger Chapuis; Sandrine Touzet; J Y Barbier; Gilles Freyer; J L Gaudin; Catherine Lombard-Bohas; Pierre-Jean Valette; Gérard Lledo; M C Gouttebel; J D Boyer; L Chassignol; H Hamon; S Claudel-Bonvoisin; E Leprince; P Amoyal; Olivier Glehen; P Darnand; Marie-Odile Heilmann; Jean Pierre Bleuse
Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?
Clinical oncology (Royal College of Radiologists (Great Britain)) 2004;16(3):196-203.
2003: Christell Ganne; Véronique Trillet-Lenoir; Isabelle Jaisson-Hot; Franck Chauvin; Christine Clippe; Marie-Odile Heilmann; Touria Hajri; Bénédicte Poncet; Catherine Heuclin; Cyrille Colin
[Which medico-economic approaches must be taken to evaluate the impact of costly molecules in oncology? The model of Herceptin in the breast metastatic cancer].
Bulletin du cancer 2003;90(11):955-60.
2003: Isabelle Jaisson-Hot; Anne-Marie Schott; Christine Clippe; Christell Ganne; Touria Hajri; Bénédicte Poncet; Véronique Trillet-Lenoir; Cyrille Colin
[Methodology of economic assessment: example in oncology].
Bulletin du cancer 2003;90(11):939-45.
2003: Olivier Glehen; Dimitri Osinsky; Eddy Cotte; F Kwiatkowski; Gilles Freyer; Sylvie Isaac; Véronique Trillet-Lenoir; Annie-Claude Sayag-Beaujard; Yves François; Jacques Vignal; François Noël Gilly
Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures.
Annals of surgical oncology 2003;10(8):863-9.
2003: Christine Clippe; Gilles Freyer; G Milano; Véronique Trillet-Lenoir
Lethal toxicity of capecitabine due to abusive folic acid prescription?
Clinical oncology (Royal College of Radiologists (Great Britain)) 2003;15(5):299-300.
2003: Christine Clippe; Véronique Trillet-Lenoir; Gilles Freyer
[Treatment of cancer: surgery, radiotherapy, chemotherapy, hormonal therapy. Multidisciplinary therapeutic decision making and informing the patient].
La Revue du praticien 2003;53(2):187-98.
2003: Gilles Freyer; Thierry Delozier; M Lichinister; D Gedouin; Philippe Bougnoux; P His; K Imadalou; Véronique Trillet-Lenoir
Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(1):35-40.
2002: Véronique Trillet-Lenoir
[A good RUM (resumes d'unite medicale) is better than two "you will have"!].
Bulletin du cancer 2002;89(11):991.
2002: Anne-Marie Schott; Touria Hajri; Cyrille Colin; François Grateau; François Noël Gilly; Etienne Tissot; Cécile Couchoud; Catherine Morestin; Véronique Trillet-Lenoir
[Usefulness of the French DRG based information system (PMSI) in the measurement of cancer activity in a multidisciplinary hospital: the Hospices Civils de Lyon].
Bulletin du cancer 2002;89(11):969-73.
2002: Véronique Trillet-Lenoir; Gilles Freyer; P Kaemmerlen; A Fond; Olivier Pellet; Catherine Lombard-Bohas; J L Gaudin; Gérard Lledo; R Mackiewicz; M C Gouttebel; H Moindrot; J D Boyer; L Chassignol; Noël Stremsdoerfer; Françoise Desseigne; J M Moreau; F Hedelius; A Moraillon; F Chapuis; Jean Pierre Bleuse; Y Barbier; Marie-Odile Heilmann; P J Valette
Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria.
The British journal of radiology 2002;75(899):903-8.
2002: Christine Clippe; Blandine Ligneau; Véronique Trillet-Lenoir
[Role of gemcitabine in the treatment of other malignant tumors].
Bulletin du cancer 2002;89 Spec No():S120-2.
2002: Sarah Taieb; Véronique Trillet-Lenoir; Loïc Rambaud; Louis Descos; Gilles Freyer
Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.
Cancer 2002;94(9):2434-40.
2002: Christine Clippe; Gilles Freyer; Marie-Hélène Bizollon; Daniel Raudrant; François Noël Gilly; Danièle Vitrey; Blandine Ligneau; Véronique Trillet-Lenoir
[Primary peritoneal tumors: report on a series of eight cases and review of the literature].
Bulletin du cancer 2002;89(4):430-6.
2001: Alain Depierre; Gilles Freyer; Jacek Jassem; Hubert Orfeuvre; Rodryg Ramlau; E Lemarie; Piotr Koralewski; Louis Mauriac; Jean-Luc Breton; Thierry Delozier; Véronique Trillet-Lenoir
Oral vinorelbine: feasibility and safety profile.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(12):1677-81.
2001: Olivier Chapet; A Corcelle-Requin; L Padovani; M H Bizollon; C Mérieux; Véronique Trillet-Lenoir; Jean-Pierre Gérard
[Anorectal neuroendocrine carcinoma and small cell carcinoma. Report of two cases].
La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne 2001;22(11):1109-15.
2001: Gilles Freyer; Blandine Ligneau; M Schlumberger; Cécile Blandy; B Contedevolx; Véronique Trillet-Lenoir; Gilbert M Lenoir; N Chau; A Dazord
Quality of life in patients at risk of medullary thyroid carcinoma and followed by a comprehensive medical network: trends for future evaluations.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(10):1461-5.
2001: C Borg; Blandine Ligneau; Véronique Trillet-Lenoir
[Dose intensity of chemotherapy in small-cell lung carcinoma].
Bulletin du cancer 2001;88(9):863-70.
2001: C Borg; Véronique Trillet-Lenoir
[General principles of dose-effect relationship].
Bulletin du cancer 2001;88(9):833-4.
2001: Gilles Freyer; Blandine Ligneau; D Kraft; Louis Descos; Véronique Trillet-Lenoir
Therapeutic advances in the management of metastatic colorectal cancer.
Expert review of anticancer therapy 2001;1(2):236-46.
2001: Véronique Trillet-Lenoir; J P Lotz; A Le Cesne; P Roy; L Avallet; A Edouard
Reflexions from the experience of the French CLEOPATRE program and concerns about the status of clinical research on small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2001;33(2-3):303-7.
2001: Moïse Namer; P Soler-Michel; Francois Turpin; P Chinet-Charrot; C de Gislain; Pierre Pouillart; Thierry Delozier; Elisabeth Luporsi; Pierre-Luc Etienne; Simon Schraub; Jean-Christophe Eymard; Daniel Serin; Gérard Ganem; Gilles Calais; P Maillart; P Colin; Véronique Trillet-Lenoir; G Prevost; D Tigaud; Pierre Clavère; P Marti; Gilles Romieu; J L Wendling
Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2001;37(9):1132-40.
2001: G Freyer; N Bossard; P Romestaing; F Mornex; Olivier Chapet; Véronique Trillet-Lenoir; J P Gérard
Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(9):2433-8.
2001: Gilles Freyer; Blandine Ligneau; Brigitte Tranchand; Claude Ardiet; Pierre-Jean Souquet; I Court-Fortune; R Riou; Paul Rebattu; E Morignat; J P Boissel; Véronique Trillet-Lenoir; P Girard
The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT).
Lung cancer (Amsterdam, Netherlands) 2001;31(2-3):247-56.
2000: E Voog; Yacine Merrouche; Véronique Trillet-Lenoir; Christine Lasset; P Y Peaud; Paul Rebattu; Sylvie Negrier
Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary.
American journal of clinical oncology 2000;23(6):614-6.
2000: E Bompas; Gilles Freyer; D Vitrey; Véronique Trillet-Lenoir
[Granulosa cell tumour: review of the literature].
Bulletin du cancer 2000;87(10):709-14.
2000: Gilles Freyer; Brigitte Tranchand; Blandine Ligneau; Claude Ardiet; Pierre-Jean Souquet; I Court-Fortune; R Riou; Paul Rebattu; J P Boissel; Véronique Trillet-Lenoir; P Girard
Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.
British journal of clinical pharmacology 2000;50(4):315-24.
2000: G Freyer; Philippe Rougier; Roland Bugat; J P Droz; Michel Marty; H Bleiberg; Dominique Mignard; L Awad; P Herait; Stéphane Culine; Véronique Trillet-Lenoir
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
British journal of cancer 2000;83(4):431-7.
2000: Jaafar Bennouna; A Monnier; Alain Rivière; Bernard Milleron; E Lemarie; Véronique Trillet-Lenoir; K Soussan-Lazard; Jocelyne Berille; Jean-Yves Douillard
A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 2000;36(9):1107-12.
2000: J Dumortier; G Freyer; A J Sasco; Lucien Frappart; thierry zenone; P Romestaing; Véronique Trillet-Lenoir
Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: report on a new case and review of the literature.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(3):355-8.
1999: Qing Wang; Christine Lasset; Françoise Desseigne; Jean-Christophe Saurin; Christine Maugard; Claudine Navarro; Eric Ruano; Louis Descos; Véronique Trillet-Lenoir; J F Bosset; Alain Puisieux
Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer.
Human genetics 1999;105(1-2):79-85.
1999: V Cottin; Dominique Arpin; Christine Lasset; J F Cordier; J Brune; Franck Chauvin; Véronique Trillet-Lenoir
Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(7):809-15.
1999: François Noël Gilly; Annie-Claude Beaujard; Jacques Bienvenu; Véronique Trillet-Lenoir; Olivier Glehen; Danielle Thouvenot; C Malcus; M Favrot; C Dumontet; Catherine Lombard-Bohas; Florence Garbit; P Y Gueugniaud; Jacques Vignal; Michèle Aymard; F Touraine-Moulin; M Roos; A Pavirani; M Courtney
Gene therapy with Adv-IL-2 in unresectable digestive cancer: phase I-II study, intermediate report.
Hepato-gastroenterology 1999;46 Suppl 1():1268-73.
1999: Jean-Marc Nabholtz; H J Senn; W R Bezwoda; D Melnychuk; L Deschênes; J Douma; T A Vandenberg; B Rapoport; R Rosso; Véronique Trillet-Lenoir; J Drbal; A Molino; J W R Nortier; D J Richel; T Nagykalnai; P Siedlecki; N Wilking; J Y Genot; Pierre Hupperets; F Pannuti; D Skarlos; E M Tomiak; Michael Murawsky; M Alakl; M Aapro
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1413-24.
1999: Gilles Freyer; A Dazord; M Schlumberger; Bernard Conte-Devolx; Blandine Ligneau; Véronique Trillet-Lenoir; Gilbert M Lenoir
Psychosocial impact of genetic testing in familial medullary-thyroid carcinoma: a multicentric pilot-evaluation.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(1):87-95.
1999: Brigitte Tranchand; C Amsellem; Etienne Chatelut; Gilles Freyer; Athanassios Iliadis; Blandine Ligneau; Véronique Trillet-Lenoir; Pierre Canal; Isabelle Lochon; Claude Ardiet
A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients.
Cancer chemotherapy and pharmacology 1999;43(4):316-22.
1998: Gilles Freyer; Blandine Ligneau; Véronique Trillet-Lenoir
Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia.
International journal of antimicrobial agents 1998;10(1):3-9.
1998: E Bompas; Gilles Freyer; Véronique Trillet-Lenoir
[Management of nonresectable non-small cell lung cancer. Recommendations of the American Society of Clinical Oncology (ASCO)].
Bulletin du cancer 1998;85(2):125-7.
1998: François Noël Gilly; Annie-Claude Sayag-Beaujard; Jacques Bienvenu; Michèle Aymard; F Touraine-Moulin; M Favrot; Véronique Trillet-Lenoir; A Pavirani; M Courtney; Yves François; Olivier Pellet; C Gaillard; Olivier Glehen; Vincent Banssillon; Jacques Vignal; M Ross
Gene therapy with AdV-IL2 (TG 1021) in unresectable digestive adenocarcinoma. Phase I-II study, first inclusions.
Advances in experimental medicine and biology 1998;451():527-30.
1997: Jean-Marc Nabholtz; B Thuerlimann; W R Bezwoda; D Melnychuk; L Deschênes; J Douma; T A Vandenberg; B Rapoport; R Rosso; Véronique Trillet-Lenoir; J Drbal; Matti S Aapro; M Alaki; Michael Murawsky; Alessandro Riva
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Oncology (Williston Park, N.Y.) 1997;11(8 Suppl 8):25-30.
1997: Véronique Trillet-Lenoir; Gilles Freyer
[Advantage of using tumor markers in colorectal and breast cancers. Guidelines of the American Society of Clinical Oncology (ASCO)].
Bulletin du cancer 1997;84(7):767-8.
1997: Gilles Freyer; Blandine Ligneau; Brigitte Tranchand; Claude Ardiet; F Serre-Debeauvais; Véronique Trillet-Lenoir
Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice.
Cancer treatment reviews 1997;23(3):153-69.
1997: Blandine Ligneau; Gilles Freyer; S Giraud; Sylvie Isaac; P Bombaron; D Espinouse; H Plauchu; G Fischer; J P Gérard; G Lenoir; Véronique Trillet-Lenoir
[Neurosarcoma associated with neurofibromatosis 1. Apropos of a case and review of the literature].
Presse médicale (Paris, France : 1983) 1997;26(10):458-63.
1996: L Falchero; Bertrand Coiffier; Benoit Guibert; Pierre-Jean Souquet; S Isaac Pinet; Véronique Trillet-Lenoir
[Malignant mesothelioma of the pleura following radiotherapy of Hodgkin disease].
Bulletin du cancer 1996;83(11):964-8.
1996: Gilles Freyer; L Descos; Véronique Trillet-Lenoir; D H Chang; Jean-Pierre Gérard
[Adjuvant treatment of colonic cancers].
Presse médicale (Paris, France : 1983) 1996;25(27):1241-6.
1996: Véronique Trillet-Lenoir; P Soler; Dominique Arpin; C Bohas; R Riou; I Court-Fortune; D Ecochard; Maurice Perol; J F Cordier
The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 1996;14(2-3):331-41.
1996: C Cotto; J Berille; Pierre-Jean Souquet; R Riou; B Croisile; Francis Turjman; B Giroux; J Brune; Véronique Trillet-Lenoir
A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1996;32A(1):69-71.
1995: Jean-Pierre Gérard; Pascale Romestaing; Jean-Michel Ardiet; Véronique Trillet-Lenoir; F P Rocher; M H Baron; F Buatois
[Current treatment of cancers of the anal canal].
Annales de chirurgie 1995;49(5):363-8; discussion 368-72.
1994: Jean-Pierre Gerard; REGIS COQUARD; D Fric; L Ayzac; Pascale Romestaing; Jean-Michel Ardiet; F P Rocher; M H Baron; Véronique Trillet-Lenoir
Curative endocavitary irradiation of small rectal cancers and preoperative radiotherapy in T2 T3 (T4) rectal cancer. A brief overview of the Lyon experience.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1994;20(6):644-7.
1994: Véronique Trillet-Lenoir; Dominique Arpin; J Brune
Bone marrow metastases detection in small cell lung cancer. A review.
Anticancer research 1994;14(6B):2795-7.
1994: J P Wagner; M A Mahe; Pascale Romestaing; F P Rocher; C Berger; Véronique Trillet-Lenoir; Jean-Pierre Gerard
Radiation therapy in the conservative treatment of carcinoma of the anal canal.
International journal of radiation oncology, biology, physics 1994;29(1):17-23.
1994: C Cotto; Elisabeth Quoix; F Thomas; S Henane; Véronique Trillet-Lenoir
Phase I study of the somatostatin analogue somatuline in refractory small-cell lung carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):290-1.
1994: Jean-Pierre Gérard; Véronique Trillet-Lenoir; J C Thalabard
[Adjuvant treatments in digestive cancers. General principles].
Gastroentérologie clinique et biologique 1994;18(8-9):710-3.
1993: Dominique Arpin; Véronique Trillet-Lenoir; Christine Lasset; Pierre-Jean Souquet; R Riou; I Yoanidis; J Guidollet; J F Cordier; J Brune
[Value of C-reactive protein determination in small cell lung cancer].
Bulletin du cancer 1993;80(12):1063-8.
1993: Véronique Trillet-Lenoir; J Brune
[Treatment of epithelial tumors of the thymus gland].
Bulletin du cancer 1993;80(12):1043-50.
1993: Véronique Trillet-Lenoir; Françoise Mornex; F Chauvin; Pierre Fournel; A Voloch; Maurice Perol; E Laennec; D Piperno; J Boyer; Jean-Michel Ardiet
Limited disease small cell lung cancer: alternating combination of doxorubicin, etoposide, ifosfamide and hyperfractionated radiotherapy. Final results of a multicentric pilot study for the Groupe Lyonnias d'Oncologie Thoracique (GLOT).
Lung cancer (Amsterdam, Netherlands) 1993;10(1-2):35-45.
1993: A Brachet; F Thévenet; François Noël Gilly; Véronique Trillet-Lenoir; A Z Tabib; J Brune; Robert Loire; Jean-Paul Gamondes
[Inflammatory pseudotumor of the superior vena cava: rare etiology of mediastinal tumor].
Annales de chirurgie 1993;47(2):170-3.
1993: Véronique Trillet-Lenoir; Dominique Arpin; J Brune
Optimal delivery of dose in cancer chemotherapy with the support of haematopoietic growth factors.
European journal of cancer (Oxford, England : 1990) 1993;29A Suppl 5():S14-6.
1993: Véronique Trillet-Lenoir; Dominique Arpin; A Mercatello; R Oskham; P A Palmer; Pierre-Jean Souquet; F Champel; J Boyer; J F Cordier; C R Franks
Combination IL-2 and cisplatinum: a promising treatment for bronchioloalveolar carcinoma?
European journal of cancer (Oxford, England : 1990) 1993;29A(13):1917-8.
1993: F Chauvin; Pierre-Jean Souquet; Véronique Trillet-Lenoir; I Court-Fortune; Maurice Perol; D Ecochard; Paul Rebattu; E Laennec; J P Bernard
[Clinical and economic evaluation of the initial assessment of small cell cancer of the lung. Alternatives to classic evaluation. LGTO. The Lyon Group of Thoracic Oncology].
Revue des maladies respiratoires 1993;10(5):445-51.
1992: Véronique Trillet-Lenoir; Christine Lasset; Dominique Arpin; C Bohas; R Riou; Maurice Perol; Pierre Fournel; Paul Rebattu; B Caillet; Yves Pacheco
[Comparison of 2 cisplatin and etoposide dosages in relapsing small cell lung cancer].
Bulletin du cancer 1992;79(12):1173-81.
1992: B Croisile; Véronique Trillet-Lenoir; J F Catajar; C Coto; G Aimard; M Trillet; J Brune
[Cerebral metastasis disclosing primary bronchogenic cancers].
Revue neurologique 1992;148(6-7):488-92.